News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Naviscan, Inc. Release: Researchers to Present Latest Technical Developments and Practical Aspects of Breast PET at the Radiological Society of North America (RSNA) Conference


11/26/2012 12:01:56 PM

SAN DIEGO, CA--(Marketwire - November 26, 2012) -

Researchers from Mayo Clinic, University of Washington and University of Pittsburgh School of Medicine will present technical advances and clinical status of Naviscan's high-resolution organ-specific PET scanner at the Radiological Society of North America 98th Scientific Assembly and Annual Meeting held November 25 - 30, 2012 in Chicago, Illinois. The presentations will take place Tuesday, November 27 in Room E353A from 8:30 a.m. - 10:00 a.m. The breast application of the scanner is commonly known as Positron Emission Mammography or PEM.

Michael O'Connor, PhD, Mayo Clinic, will present Technical Developments in Molecular Imaging of the Breast. In this educational session, Dr. O'Connor will review PEM, MBI and BSGI starting with a discussion of detector configurations and reviewing current applications of molecular breast imaging in the clinical care cycle. The session will conclude with a discussion of potential future applications of this technology in understanding breast disease.

Lawrence MacDonald, PhD, University of Washington, Seattle will present Physics and Practical Aspects of Breast PET (PEM). In this physics session, Dr. MacDonald reviews the technological developments in dedicated breast PET imaging technologies including the factors that affect quantitation of breast lesions. New exciting results in FDG dose reductions and new areas of future research will be summarized.

Wendie A. Berg, MD, PhD, University of Pittsburgh School of Medicine, will present Practical Aspects and Clinical Status of Breast PET (PEM). Dr. Berg will review the applications of dedicated high resolution PET devices (PEM) and describe the interpretive criteria in this clinical session. New results in FDG dose reduction and future research directions will be discussed.

"These sessions demonstrate the expanding role and utility of PEM in the diagnosis of breast cancer," stated Paul J. Mirabella, CEO, Naviscan, Inc. "Because of the continued research of these and other esteemed clinicians utilizing PEM, the practical aspects of breast cancer diagnosis and treatment are ever improving."

About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, visit www.naviscan.com.


Contact Information
Joleen Schultz
Naviscan Marketing Communications
321 Medical Launch
Tel: +1.858.455.5500
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES